- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Small Cell Lung Cancer | Clinical
Choosing Therapy for NSCLC to SCLC Transformation in EGFR+ Disease
May 19, 2022
Ravi Salgia, MD, PhD, discusses how to address and treat transformation from non–small cell lung cancer to small cell lung cancer.
Key Signs of SCLC Transformation in Patients With EGFR+ NSCLC
May 12, 2022
Ravi Salgia, MD, PhD, discusses the ways in which oncologists can watch out for non-small cell lung cancer that transforms to small-cell lung cancer.
Adebrelimab With Chemotherapy Extends Overall Survival in SCLC
April 22, 2022
Based on phase 3 study results of patients with extensive-stage small cell lung cancer, treatment with adebrelimab plus chemotherapy prolonged overall survival compared with matched placebo.
Examining Transformation of NSCLC to SCLC in EGFR+ Disease
April 19, 2022
Ravi Salgia, MD, PhD, discusses the results from a study of LB-100 combined with chemotherapy or immunotherapy to address transformation from non-small cell lung cancer to small cell lung cancer.
FDA Grants Orphan Drug Status to Toripalimab for Small Cell Lung Cancer
April 14, 2022
The FDA has granted orphan drug designation to toripalimab for the treatment of patients with small cell lung cancer.
FDA Grants Orphan Drug Status to Serplulimab for Small Cell Lung Cancer
April 07, 2022
The FDA has granted orphan drug designation to serplulimab for the treatment of patients with small cell lung cancer.
Retrospective Study Shows Adoption of Immunotherapy in ES-SCLC
April 01, 2022
Eric Nadler, MD, MPP, discusses the design and goals of a retrospective study of real-world adoption of atezolizumab immunotherapy in extensive-stage small cell lung cancer.
PP2A Inhibitions May Address Transformation of NSCLC to SCLC in Patients With EGFR+ Disease
March 29, 2022
In an interview with Targeted Oncology, Ravi Salgia, MD, PhD, discussed the research leading to the first-in-human study of LB-100 combined with chemotherapy or immunotherapy to address transformation to small cell lung cancer.
Selecting Treatment for Late-Stage SCLC
March 25, 2022
Afshin Dowlati, MD, discusses treatment decision-making for patients with late-stage small cell lung cancer.